The sulfonamide corrosion inhibitors are compounds of formula A or formula B, as follows: ##STR00001##
A method of synthesizing the sulfonamide corrosion inhibitors includes functionalizing a polyamine precursor with a sulfonyl chloride derivative by dehydrochlorination. The polyamine precursor may be bis(3-aminopropyl)amine and the sulfonyl chloride derivative may be methanesulfonyl chloride. The sulfonamide corrosion inhibitors may be applied alone or in any combination as corrosion inhibitors of a metal and are shown to be effective inhibitors of corrosion of iron or iron alloys in acidic conditions.

The sulfonamide corrosion inhibitors are compounds of formula A or formula B, as follows: ##STR00001##
A method of synthesizing the sulfonamide corrosion inhibitors includes functionalizing a polyamine precursor with a sulfonyl chloride derivative by dehydrochlorination. The polyamine precursor may be bis(3-aminopropyl)amine and the sulfonyl chloride derivative may be methanesulfonyl chloride. The sulfonamide corrosion inhibitors may be applied alone or in any combination as corrosion inhibitors of a metal and are shown to be effective inhibitors of corrosion of iron or iron alloys in acidic conditions.

The sulfonamide corrosion inhibitors are compounds of formula A or formula B, as follows: ##STR00001##
A method of synthesizing the sulfonamide corrosion inhibitors includes functionalizing a polyamine precursor with a sulfonyl chloride derivative by dehydrochlorination. The polyamine precursor may be bis(3-aminopropyl)amine and the sulfonyl chloride derivative may be methanesulfonyl chloride. The sulfonamide corrosion inhibitors may be applied alone or in any combination as corrosion inhibitors of a metal and are shown to be effective inhibitors of corrosion of iron or iron alloys in acidic conditions.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The present invention relates to a process for hydrogenating a substrate including a carbon-heteroatom double bond, the process including the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): ##STR00001##
R.sub.1-10, A and Hal are as defined in the specification. The present invention also provides processes for the preparation of the complex of formula (I) and intermediates thereof.

The present invention relates to a process for hydrogenating a substrate including a carbon-heteroatom double bond, the process including the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): ##STR00001##
R.sub.1-10, A and Hal are as defined in the specification. The present invention also provides processes for the preparation of the complex of formula (I) and intermediates thereof.

The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##